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PEER REVIEW AND PUBLICATION:
LESSONS FOR LAWYERS*
Susan Haack*
[A] pertinent consideration [in determining whether a theory
or technique is scientific knowledge that will assist the trier
of fact] is whether the theory or technique has been sub-
jected to peer review and publication.
-Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993)1
The phrase "peer review" connotes the evaluation ("review")
of scientific or other scholarly work by others presumed to have
expertise in the relevant field ("peers"). Specifically, and most to
the present purpose, it refers to the evaluation of submitted
manuscripts to determine what work is published in professional
journals and what books are published by academic presses (in
which context it is also called "refereeing," "editorial peer review,"
or "pre-publication peer review"). 2 Occasionally, however, the
phrase is used in a much broader sense, to cover the whole long-
run history of the scrutiny of a scientist's work within the scien-
tific community, and of others' efforts to build on it, 3 a long-run
* This Article was developed from a talk entitled "Scrutinizing Peer Review" given
at the National Institute of Justice Conference on Science and the Law held in St. Peters-
burg, Florida, in September 2005. It appears here by invitation.
** © 2007, Susan Haack. All rights reserved. Distinguished Professor in the Humani-
ties, Cooper Senior Scholar in Arts and Sciences, Professor of Philosophy, and Professor of
Law, University of Miami.
1. Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 593 (1993) [hereinafter
"Daubert (1993)"J.
2. The phrase also sometimes refers to the evaluation of clinical performance by
senior practitioners in a field (in which context it is called "clinical peer review"), to the
evaluation of grant proposals to decide what projects are funded (in which context it is
called "grant peer review" or "merit review"), and to the evaluation of abstracts, or some-
times submitted papers, to determine what is presented at conferences.
3. "In the broadest sense of the term, peer review can be said to have existed ever
since people began to identify and communicate what they thought was new knowledge."
David A. Kronick, Peer Review in 18th-Century Scientific Journalism, 263 JAMA 1321,
1321 (1990).
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process of which peer review in the narrower sense is only a small
part.
These two conceptions of peer review, the narrow and the
broad, both came into play in the arguments over the admissibil-
ity of the plaintiffs' expert testimony in Daubert.4 In 1989, grant-
ing Merrell Dow's motion for summary judgment on the ground
that the Dauberts' proffered causation evidence was inadmissible,
the District Court had stressed that "none of the published stud-
ies show a statistically significant association between the use of
Bendectin and birth defects";5 and affirming this decision in 1991,
observing that "no published epidemiological study had demon-
strated a statistically significant association between Bendectin
and birth defects," and that "the normal peer[-]review process ...
is one of the hallmarks of reliable scientific investigation," Judge
Kozinski also took peer-reviewed publication to be a key factor. 6
But in 1993, when the case came to the Supreme Court, an
amicus brief from Chubin et al. criticized the lower courts' reli-
ance on peer-reviewed publication, arguing that "the peer review
system is designed to provide a common and convenient starting
point for scientific debate, not the final summation of existing sci-
entific knowledge," and that "contrary to the 'generally accepted'
myth, publication of an article in a peer review journal is no as-
surance that the research, data, methodologies, [or] analyses...
are true, accurate, . . . reliable, or certain or that they represent
'good science."' 7 And while Justice Blackmun's ruling for the
Court included "peer review and publication" as one factor to
which courts might look to determine whether expert scientific
testimony is "reliable" in the sense required to make it admissi-
ble, it did so in a very hedged and cautious way-acknowledging
that pre-publication peer review doesn't guarantee "evidentiary
reliability" and may hold back well-grounded but innovative
work; and that a much better indicator is survival of the long-run
4. Effie J. Chan, Student Author, The "Brave New World" of Daubert: True Peer Re-
view, Editorial Peer Review, and Scientific Validity, 70 N.Y.U. L. Rev. 100, 113 (1995).
5. Daubert v. Merrell Dow Pharms., Inc., 727 F. Supp. 570, 575 (S.D. Cal. 1989) [here-
inafter "Daubert (1989)"].
6. Daubert v. Merrell Dow Pharms., Inc., 951 F.2d 1128, 1129, 1131 n. 3 (9th Cir.
1991) [hereinafter "Daubert (1991)"].
7. Br. of Daryl E. Chubin et al. as Amici Curiae in Support of Petrs. at 8, 13, Daubert
(1993), 509 U.S. 579 (typeface altered from original) [hereinafter Amici Br. of Chubin].
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scrutiny of the scientific community, i.e., peer review in the broad
sense.
8
Finally, in 1995, ruling on the case on remand from the Su-
preme Court, and now acknowledging, as Justice Blackmun had,
that peer-reviewed publication is no guarantee that testimony is
trustworthy, Judge Kozinski argued that nevertheless, the fact
"[t]hat the research is accepted for publication in a reputable sci-
entific journal... is a significant indication that.., it meets at
least the minimal criteria of good science."9 So, since "[n]one of
the plaintiffs' experts has published his work on Bendectin in a
scientific journal," the Court affirmed the lower court's summary
judgment once again.'0
The aim here is to understand how the peer-review process
works, how good an indicator it is that scientific testimony is "re-
liable" in the legally relevant sense, and how courts might best
use this Daubert factor. So for most of what follows, the focus will
be on peer review in the narrow sense-pre-publication peer re-
view. The starting point, in Part I, will be a sketch of the origins
of this practice, the ragged process by which it gradually became
standard at scientific and medical journals, and the many roles it
now plays; the next step, in Part II, will be to articulate the ra-
tionale for pre-publication peer review, and the inherent limita-
tions of the system as a quality-control mechanism; and the next,
in Part III, will be an exploration of the changes in science, in sci-
entific publication, and in the academy that have put the peer-
review system under severe strain, and of some recent instances
in which flawed or even fraudulent work has passed peer review.
But in Part IV, an examination of Justice Blackmun's obser-
vations about "peer review and publication" in Daubert, the broad
sense of "peer review" will play a part alongside the narrow. The
argument here will be, in brief, that neither Justice Blackmun's
observation that peer-reviewed publication is not necessary or
sufficient for evidentiary reliability, and that surviving the long-
term process of review by the scientific community is a much bet-
ter indicator of scientific validity, nor his advice to courts-that
8. Daubert (1993), 509 U.S. at 593.
9. Daubert v. Merrell Dow Pharms., Inc., 43 F.3d 1311, 1318 (9th Cir. 1995) [herein-
after "Daubert (1995)"].
10. Id. at 1318, 1332.
2007]
Stetson Law Review
peer-reviewed publication may be relevant, but is not a disposi-
tive consideration in determining admissibility-is of much prac-
tical help.
Subsequently, whether they have excluded testimony in part
because it was not based on peer-reviewed publication, or admit-
ted it even though it was not so based, courts seem by and large
not to have asked the questions that might throw light on what
peer-reviewed publication, or its absence, means in a particular
instance. But as we shall see in Part V, a Pennsylvania court's
uncommonly common-sense scrutiny of the peer-reviewed Ben-
dectin literature reveals how weak a reed "peer review and publi-
cation" can be-and leaves one wondering rather uncomfortably
about the way this "Daubert factor" got on the legal radar screen
in the first place.1
I. PRE-PUBLICATION PEER REVIEW ITS HISTORICAL
ROOTS AND PRESENT ROLES
Scientists have always been concerned that their work be ac-
knowledged as theirs and have worried about what Robert Boyle
charmingly described as "philosophicall robbery," a.k.a. plagia-
rism. 12 Even before the Philosophical Transactions of the Royal
Society of London were inaugurated in 1655, the Society would
give its official stamp to a scientist's priority in discovery by re-
cording the date on which it received a letter announcing an ex-
periment or observation.13 As Henry Oldenburg, the first editor of
the Transactions, told Boyle, the Society would be "very carefull of
registring as well the person and time of any new matter, im-
parted to ym, as the matter itselfe; whereby the honor of ye in-
vention will be inviolably preserved to all posterity."1 4 Gradually
the Transactions began to indicate which work had and which
had not been evaluated by representatives of the Society before
publication; and by 1702 the Journal de Scavans, founded just
before the Transactions, had assigned responsibility for screening
11. Blum v. Merrell Dow Pharms., Inc., 764 A.2d 1, 3 (Pa. 2000).
12. Harriet Zuckerman & Robert K. Merton, Patterns of Evaluation in Science: Institu-
tionalism, Structure, and Functions of the Referee System, 9 Minerva 66, 70 (1971).
13. Id.
14. Id. (citing The Correspondence of Henry Oldenburg vol. 1, 319 (A. Rupert Hall &
Marie Boas Hall eds. & trans., U. Wis. Press 1966)).
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submissions in a given area to various members of the editorial
board. 15
In the course of the eighteenth century several other impor-
tant medical and scientific publications adopted what we would
now call "peer review": in 1731, the preface to the first volume of
the Medical Essays and Observations published by the Royal So-
ciety of Edinburgh announced that "[m]emoirs sent by correspon-
dence are distributed according to the subject matter to those
members who are most versed in these matters";16 in 1752, the
Royal Society set up a committee authorized to call on "any other
members of the Society who are knowing and well skilled in that
particular branch of Science that shall happen to be the subject
matter" of an article submitted to the Transactions;17 in 1782, the
regulations of the Acad6mie Royale de M6decine stated that
"[n]othing will be printed in the Histoire, or in the Receuil des
memoires of the Society... which assemblies especially called for
this purpose have not decided by a majority vote to publish";18
and in 1785, the Literary and Philosophical Society of Manchester
set up a reviewing committee to select papers "with as much im-
partiality, and as strict attention to their comparative merits" as
possible. 19
According to historian John Burnham, the spread and evolu-
tion of the practice of pre-publication peer review through the
nineteenth century and the early decades of the twentieth was
neither systematic nor orderly. 20 Some of the earliest medical
journals of the nineteenth century were, as Burnham puts it,
"personal vehicle[s]" for editors like Thomas Wakely, founder of
The Lancet, or Henry Maunsell, a founder of the Dublin Medical
Press, who subsequently also became owner of the Dublin Eve-
15. Stephen Lock, A Difficult Balance: Editorial Peer Review in Medicine 2 (Nuffield
Provincial Hospitals Trust 1985).
16. Kronick, supra n. 3, at 1321 (citing I Essais et observations de medecine de la So-
cit6 d'Edinbourg vol. 1, preface (1740)).
17. Id. (citing J.M. Ziman, Information, Communication, Knowledge, 224 Nature 318,
318 (1969)).
18. Id. at 1321-1322 (citing 13 Histoire de lAcadgmie Royale de Midecine 19-21
(1782)).
19. Id. at 1322 (citing 1 Memoirs of the Literary and Philosophical Society of Manches-
ter preface (1785)).
20. John C. Burnham, The Evolution of Editorial Peer Review, 263 JAMA 1323, 1327-
1328 (1990).
2007]
Stetson Law Review
ning Mail.21 Somewhat closer to present-day scientific and medi-
cal journals were the official publications of European (especially
German) research institutes; these more specialized fora relied on
the expert judgment of the editor or the colleagues who made up
his editorial staff, but were essentially outlets for the work of
members of the institute.22
But in the early days of both scientific and medical publishing
an editor's problem was more likely to be finding enough material
to fill his pages than deciding which of too many articles to pub-
lish. In 1876, a commentator observed that ". . . the demand for
brief papers and reports of single cases, exceeds the supply.23 The
weekly and monthly periodicals are omnivorous and insatiable in
their requests for contributions";24 even in 1921 the editor of The
Journal of Neurology and Psychopathology was complaining to a
correspondent about the difficulty of getting enough material for
his journal.25 It was only after World War II that peer review as
we now know it became common practice in medical and scientific
journals; 26 for by this time a significant shift in the number of pa-
pers offered meant that editors were looking, not for material to
fill their pages, but for a way to select which papers they would
publish.27
By now, pre-publication peer review is routine at medical and
scientific journals, 28 and standard procedure, too, in scholarly
publication and in other areas, including the humanities (though
not the law reviews).29 It has, in consequence, also become a very
21. Id. at 1324.
22. Id.
23. Id. at 1325.
24. Id. (citing John Shaw Billings, Literature and Institutions, 72 Am. J. Med. Sci. 439,
460 (1876)).
25. Id. (citing Ltr. from C. Stanford Read to Smith Ely Jelliffe (Feb. 3, 1921), in Papers
of Smith Ely Jelliffe, 1866-1940 (on file with Library of Congress, Washington, D.C., Box
16)).
26. Marjorie Sun, Peer Review Comes under Peer Review, 244 Sci. 910, 910 (1989).
James McKeen Cattell, who edited Science from 1894 until his death in 1945, reportedly
relied heavily on his son (who had a degree in physiology from Harvard) to help screen
submissions; but when the American Association for the Advancement of Science took over
the journal in 1945, a system of peer reviewing was instituted. Id.
27. Burnham, supra n. 20, at 1326-1327.
28. By 1985 at least three-quarters of major scientific journals in the West relied on
peer review. Lock, supra n. 15, at 3. In 1980, the 100 Soviet medical journals also used
peer review. Id.
29. At law reviews it is usually student editors, not faculty, who decide what papers
[Vol. 36
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important factor in the economics of medical, scientific, and other
academic publishing; the prestige of the big scientific and medical
publishing houses and of the academic presses, and hence the
high prices they can command for their publications, 30 derives in
part from these publications' being perceived as somehow "certi-
fied" by peer review.
Moreover, peer review is now deeply entrenched in the tenure
and promotion systems of the universities, which may require
peer-reviewed publications or look less favorably on publications
that are not peer-reviewed, and may count a faculty member's
acting as referee for scholarly journals or presses as part of his or
her "service."31 In fact, universities often use pre-publication peer
review as a proxy-it is tempting to say, as a lazy substitute-for
substantive assessment of the quality of a person's work. As an
unusually candid editorial in Nature complained, "universities...
have slipped into the sloppy habit of substituting for their own
judgement of their own achievements the judgement of external
assessors as delivered by the appropriate sub-net of the peer-
review system." 32
As Percy Bridgman once observed, while "[a] dog is content to
turn around three times before lying down," a human being would
have to think up some reason why this is the best way to lie down;
"[t]here is not a single human institution which has not origi-
nated in hit or miss fashion, but, nevertheless, every one of these
institutions is justified by some rationalizing argument as the
best possible."33 So it is no surprise that, as pre-publication peer
are accepted. See Richard A. Posner, Against the Law Reviews, 2004 Leg. Affairs 57, 57
(Nov./Dec. 2004) (acknowledging that student editors ultimately decide which articles to
publish and arguing that the law review publication process is, for this reason, less rigor-
ously controlled than publication in other academic fields); but see Amici Br. of Chubin,
supra n. 7, at 8 n. 8 (pointing out that law reviews are in some respects more rigorous,
since student editors, who check every citation and footnote, spend far more time on pa-
pers than peer reviewers for scientific journals can do).
30. In October 2003 scientists at the University of California, San Francisco staged a
protest over Elsevier's $91,000 bill for six biology journals; eventually the university nego-
tiated "a 25% price reduction to $7.7 million a year for 1,200 Elsevier periodicals." Bernard
Wysocki Jr., Peer Pressure: Scholarly Journals' Premier Status Is Diluted by Web, Wall St.
J. Al, A8 (May 23, 2005).
31. Editorial, Is Science Really a Pack of Lies? 303 Nature 361, 361 (1983).
32. Id.
33. Percy Bridgman, The Struggle for Intellectual Integrity, in Reflections of a Physi-
cist 361, 368 (2d ed., Phil. Lib 1955).
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review has spread and become entrenched in academic publishing
and in the academy itself, some are tempted to exaggerate its vir-
tues-to think of the system, not just as a rough-and-ready pre-
liminary filter, but as a strong indication of quality. In 1968, John
Ziman described the referee as "the lynchpin [sic] about which the
whole business of science is pivoted"; and more recently, life sci-
entist Paul Gross writes that he sees "peer-reviewed" as-
speaking "loosely, but not incorrectly"-a kind of "antonym" for
"biased."34
But even if the pre-publication peer-review system worked
perfectly, it would be inherently limited in what it could do to en-
sure quality--of which, in any case, "reliability" in the legally
relevant sense is only one dimension; what's more, there is good
reason to fear that, because of changes in the scale and culture of
the sciences since the system became standard, the system now
works very imperfectly indeed.
II. PRE-PUBLICATION PEER REVIEW ITS RATIONALE
AND INHERENT LIMITATIONS
In 1946, just as the practice was becoming standard proce-
dure at scientific journals, Michael Polanyi gave the classic
statement of an epistemological rationale for pre-publication peer
review. Some system for rationing limited publication opportuni-
ties is essential, he argued, for the scientific enterprise depends
on effective evidence-sharing and mutual scrutiny, and without
such a system scientists will be obliged to waste their time sifting
through the work of cranks and incompetents looking for worth-
while stuff as follows:
Suppose... that no limitations of value were imposed on the
publication of scientific contributions in journals. The selec-
tion-which is indispensable in view of the limited space-
would then have to be done by some neutral method-say
drawing lots. Immediately the journals would be flooded
with rubbish and valuable work would be crowded out....
Cranks are always abounding who will send in spates of
nonsense. Immature, confused, fantastic, or else plodding,
34. E-mail from Paul R. Gross, Prof. of Life Scis., U. of Va., to Susan Haack, Peer Re-
view (July 11, 2005, 3:46 p.m. EDT) (copy on file with the Author).
[Vol. 36
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pedestrian, irrelevant material would be pouring in. Swin-
dlers and bunglers combining all variants of deception and
self-deception would seek publicity. Buried among so much
that is specious or slipshod, the few remaining valuable pub-
lications could hardly have a chance of being recognized. 35
Rationing by pre-publication peer review, Polanyi continued, is a
way to ensure that what is published at least meets minimal
standards of professional competence as follows:
No proposed contribution to science has a chance of becom-
ing generally known unless it is published in print; and its
chances of recognition are very poor unless it is published in
one of the leading scientific journals. The referees and edi-
tors of these journals are responsible for excluding all matter
which they consider unsound or irrelevant. They are charged
with guarding a minimum standard for all published scien-
tific literature. 36
The key phrases for our purposes are "unsound or irrelevant" and
"guarding a minimum standard."37
"Unsound" and "minimum standard" make the point that pre-
publication peer review cannot be expected to guarantee truth,
sound methodology, rigorous statistics, etc. From the very begin-
ning, scientific editors have stressed that they and their reviewers
have no choice but to rely on the integrity of authors. In 1665,
Denis de Sallo, the first editor of the Journal des Scavans, wrote
in the first issue that "we aim to report the ideas of others with-
out guaranteeing them";38 the Edinburgh Society's 1731 state-
ment of its refereeing policy concludes with the observation that
"[riesponsibility concerning the truth of facts, the soundness of
reasoning, in the accuracy of calculations is wholly disclaimed:
and must rest alone, on the knowledge, judgement, or ability of
the authors who have respectfully furnished such communica-
tions."39
35. Michael Polanyi, Science, Faith and Society 35-36 (Oxford U. Press 1946).
36. Id. at 33.
37. Id.
38. Drummond Rennie, Editorial Peer Review: Its Development and Rationale, in Peer
Review in Health Sciences 1, 2 (Fiona Godlee & Tom Jefferson eds., 2d ed., BMJ Publg.
Group 2003).
39. Kronick, supra n. 3, at 1322.
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And Polanyi's "irrelevant" reminds us that editors and peer-
reviewers are not concerned only with truth, methodological
soundness, and such; they also care, reasonably enough, about the
interest of the work, the readability of the article, and its suitabil-
ity for this particular journal. 40 As the former editor of the
Journal of the National Cancer Institute puts it, writing of
"[r]eliability ... and other inappropriate goals in peer review,"
"editorial decisions can, do, and should make use of criteria...
[such as] originality, the suitability of the topic for a given jour-
nal,.., the need for a balance of topics in journals with broad cov-
erage, [and] the importance of findings to readers .... 41
Polanyi was clear that what gives scientific results some au-
thority is not peer-reviewed publication as such, but the following
that happens after work is published:
On its publication a paper is laid open to scrutiny by all sci-
entists who will proceed to form, and possibly also to ex-
press, an opinion on its value. They may doubt or altogether
reject its claims, while its author will probably defend them.
After a time a more or less settled opinion will prevail. The
third stage of public scrutiny through which a contribution
to science must pass in order to become generally known and
established is its incorporation in text-books or at least
standard books of reference. 42
Moreover, he acknowledged that the peer-review system will
succeed even in the modest task of "guarding a minimum stan-
dard" only on certain following assumptions:
If each scientist set to work every morning with the inten-
tion of doing the best bit of safe charlatanry which would
just help him into a good post, there would soon exist no ef-
fective standards by which such deception could be de-
tected.... Only if scientists remain loyal to scientific ideals
40. See Polanyi, supra n. 35, at 33 (suggesting that referees and editors try to ensure
that all published literature meets minimum standards of quality and is relevant to the
journal).
41. John C. Bailar, Reliability, Fairness, Objectivity and Other Inappropriate Goals in
Peer Review, 14 Behavioral & Brain Scis. 137, 138 (1991).
42. Polanyi, supra n. 35, at 33-34.
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rather than try to achieve success with their fellow scientists
can they form a community which will uphold these ideals.
43
Obviously (though Polanyi doesn't say so explicitly), the effective-
ness of the system depends not only on the integrity of authors,
but also on the integrity of reviewers, editors, and publishers.
And the problem is not only that it will fail if every scientist sets
to work to do "the best bit of safe charlatanry" he can get away
with; it is also that peer review will function less effectively the
heavier the burdens on reviewers and editors, the greater the
pressures on journals, and the greater the temptations for scien-
tists to cut corners, or to fudge, trim, or even fake results.
III. PRE-PUBLICATION PEER REVIEW- RECENT STRESSES
AND STRAINS, FLAWS AND FAILURES
Even in ideal circumstances, reviewers are better placed to
judge the readability of a paper or the interest of its topic or re-
sults than its truth or accuracy, and may in good faith reject im-
portant work that is too innovative to seem plausible; so perhaps
it is not surprising that by 1994 historian of science Horace Free-
land Judson, describing the "structural transformations... tak-
ing place in the sciences," included "declining standards and the
growing, built-in tendency toward corruption of the peer-review
and refereeing processes" on his list.44 For today there are many
pressures putting the peer-review system under severe strain: the
explosion of scientific and medical publications; the increasing
financial influence of large drug companies on the medical jour-
nals; the pressures on young scientists to get grants and to pub-
lish; the temptations to celebrity-seeking; the burgeoning expert-
witness business; and so on. 45
There are variations among the scientific and medical jour-
nals, but the peer-review refereeing process usually works
roughly like this: an editor carries out what Lock describes as
"triage": "classifying articles into self-evident masterpieces, obvi-
43. Id. at 40.
44. Horace Freeland Judson, Structural Thansformations of the Sciences and the End
of Peer Review, 272 JAMA 92, 92 (1994).
45. Susan Haack, Defending Science-Within Reason: Between Scientism and Cyni-
cism 27-29, 107-109 (Prometheus Bks. 2003).
20071
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ous rubbish, and the remainder.., needing careful considera-
tion";46 for this third group-the large majority-the editor then
chooses one or two (seldom more) reviewers to look at each paper
chosen, generally informing reviewers of authors' names, but not
vice versa;47 reviewers are usually given a checklist against which
to check for various aspects of style and presentation and certain
kinds of obvious error;48 the reviewers are given a time limit, of-
ten of no more than two weeks, to respond with their assessment
and recommendation; 49 and they spend an average of around 2.4
hours evaluating a manuscript-which usually involves, not sim-
ply giving a "yes or no" verdict, but making suggestions as to how
the paper might be improved.5 0 Many journals don't check the
statistical calculations in accepted papers;5' and reviewers are in
46. Lock, supra n. 15, at 6.
47. Some journals are moving towards "open" review in which authors also know re-
viewers' names. See Richard Smith, Peer Review: Reform or Revolution? 315 British Med.
J. 759, 760 (1997) (arguing that open review is the most ethical form because it places
authors and reviewers in equal positions and allows for increased accountability). By con-
trast, in philosophy journals, and so far as I know in humanities journals generally, both
reviewers' and authors' names are normally "blinded." (I routinely decline to referee a
paper if the author is known to me.)
48. Water Resources Research Inst. of U.N.C., Report Guidelines for Authors-
Editorial Checklist, http://www.ncsu.edu/wrri/reports/guidelines/edchecklist.html (accessed
Oct. 1, 2006).
49. In philosophy journals, and so far as I know in humanities journals generally, the
time allowed is much longer.
50. See e.g. Stephen Lock & Jane Smith, What Do Peer Reviewers Do? 263 JAMA 1341,
1342 (1990) (indicating that study results show that reviewers spend less than 2 hours
reviewing a manuscript); Alfred Yankauer, Who Are the Peer Reviewers and How Much Do
They Review? 263 JAMA 1338, 1339 (1990) (reporting that for 12 issues of American Jour-
nal of Public Health the average review time was 2.4 hours that resulted in 3360 hours of
uncompensated time).
51. See Martin J. Gardner & Jane Bond, An Exploratory Study of Statistical Assess-
ment of Papers Published in The British Medical Journal, 263 JAMA 1355, 1355 (1990)
(quoting statistics from a study on accuracy of papers submitted to The British Medical
Journal; only 11% of submitted papers were found to be statistically accurate, and only
84% of published papers were accurate); Ann C. Weller, Editorial Peer Review in US Medi-
cal Journals, 263 JAMA 1344, 1345 (1990) (reporting that most journals do not make any
independent check of authors' statistical calculations); see also Dianne Bryant et al., How
Many Patients? How Many Limbs? Analysis of Patients or Limbs in the Orthopedic Litera-
ture: A Systematic Review, 88 J. Bone & Joint Surgery 41, 41 (2006) (concluding that 42%
of clinical studies in highly-rated orthopedic journals are biased by the inclusion of multi-
ple observations of different limbs of single individuals); Emili Garcia-Berthou & Carles
Alcaraz, Incongruence between Test Statistics and P Values in Medical Papers, 4 BMC
Medical Research Methodology 13, "Results and Discussion" (2004) (finding that "11.6%
(21 of 181) and 11.1% (7 of 63) of the statistical results published in Nature and BMJ re-
spectively during 2001 were incongruent" and noting that "[alt least one such error ap-
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no position to repeat authors' experiments or studies, which will
ordinarily have taken a good deal of time and/or money. Accep-
tance rates vary widely from field to field; where the rate is low,
most of the papers initially submitted to but rejected by one or
more of the most desirable journals eventually appear in some
lower-ranked publication, and a paper "may have been rejected by
ten or twenty journals before it is finally accepted." 52 Textbook
chapters are usually invited, not peer-reviewed. Nor are all the
articles in "peer-review" journals peer-reviewed; some are invited,
and some appear by editorial privilege; and sometimes the au-
thors have been asked-as I have been asked myself-to nomi-
nate their own reviewers.
As the scale of the operation increases, with more and more
papers submitted to more and more journals, the quality of re-
viewers and the time and attention they can give to their task is
likely to decline. As the career pressures on scientists intensify,
the temptation grows for reviewers to recommend acceptance of
work they perceive as likely to advance their careers, to recom-
mend rejection of work they perceive as a professional threat, or
to plagiarize ideas from work they are asked to review. 53 And as
pressures on the journals and their staff increase, the hope of
prestige and profit causes further distortions: some journals sus-
pend the peer-review process when they publish symposia spon-
sored by pharmaceutical companies (for which the journal may
charge the company a significant fee); some reap large sums from
the sale of large numbers of reprints to the companies con-
peared in 38% (12 of 32) and 25% (3 of 12) of the papers of Nature and BMJ respectively,
indicating that they are widespread and not concentrated in a few papers"); Julie A.
Neville et al., Errors in the Archives of Dermatology and the Journal of the American
Academy of Dermatology from January through December 2003, 142 Archives Dermatol-
ogy 737, 738 (2006) (reporting that from January through December 2003, the Archives of
Dermatology and the Journal of the American Academy of Dermatology published 364
studies where "59 (38.1%) of 155 [that used statistical analysis] contained errors or omis-
sions in statistical methods or the presentation of the results"); A. Vail & E. Gardener,
Common Statistical Errors in the Design and Analysis of Subfertility Trials, 18 Human
Reprod. 1000, 1000 (2003) (reporting that of thirty-nine trials studied, "[slix trials were
fatally flawed by design" and "[o]nly five trials reported live birth rates sufficiently to
allow valid meta-analysis").
52. Amici Br. of Chubin, supra n. 7, at 16.
53. D.H. Osmond, Malice's Wonderland: Research Funding and Peer Review, 14 J.
Neurobiology 95, 105 (1983).
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cerned; 54 some put pressure on authors to cite other papers in the
same journal, thus raising its "impact factor" and boosting library
orders; 55 and so on.
Editors themselves have begun to express concern. Richard
Smith, editor of The Lancet, writes that peer review is "expensive,
slow, prone to bias, open to abuse, possibly anti-innovatory, and
unable to detect fraud." 56 Drummond Rennie, associate editor of
the Journal of the American Medical Association (JAMA), is even
more outspoken: "[t]here seems to be no study too fragmented, no
hypothesis too trivial, no literature citation too biased or too ego-
tistical, no design too warped, no methodology too bungled,... no
argument too circular, no conclusion too trifling or too unjustified,
and no grammar or syntax too offensive for a paper to end up in
print."57
According to a study reported in JAMA in 2004, a survey of
122 published articles found that fifty percent of efficacy and
sixty-five percent of harm outcomes were incompletely reported. 58
According to a study reported in Nature in 2005, more than ten
percent of 3,247 scientists polled admitted withholding details of
methodology or results from papers or proposals; more than fif-
teen percent admitted dropping observations or data points; and
more than twenty-seven percent admitted keeping inadequate
records of research projects. 59 According to a study reported in
JAMA the same year, of forty-five highly cited studies published
in prestigious journals and claiming effective medical interven-
tions, fourteen were later contradicted in whole or part by other
54. "Two editors reported that their journals charged $400 to $1,500 per page to pub-
lish symposiums, and another reported charging a flat fee of $100,000. The journals
charged an average of $15 per reprint, and reprint requests for symposiums [averaged]
25,000." Lisa A. Bero et al., The Publication of Sponsored Symposiums in Medical Jour-
nals, 327 New Eng. J. Med. 1135, 1136-1137 (1992).
55. Sharon Begley, Science Journals Artfully Try to Boost Their Rankings, Wall St. J.
B1, B8 (June 5, 2006).
56. Smith, supra n. 47, at 759.
57. Drummond Rennie, Guarding the Guardians: A Conference on Editorial Peer Re-
view, 256 JAMA 2391, 2391 (1986).
58. An-Wen Chan et al., Empirical Evidence for Selective Reporting of Outcomes in
Randomized Trials, 291 JAMA 2457, 2457 (2004).
59. Brian C. Martinson et al., Scientists Behaving Badly, 435 Nature 737, 737 (2005).
[Vol. 36
Peer Review and Publication
studies.60 And according to an article published in the Rockefeller
University's Scientist magazine in spring 2006, over the three
years in which the Journal of Cell Biology has been examining
every image in every paper accepted, checking for alterations
made in Adobe Photoshop, 14 of 1,400 articles were rejected after
fraudulent image alteration was detected.6 1
Moreover, other studies suggest that even after serious scien-
tific misconduct or outright fraud has been discovered, the process
of cleaning up the scientific literature so that such work is re-
tracted and others' innocent citations to it corrected is at best
patchy and uneven.6 2 For example, a year after the Office of Re-
search Integrity informed ten journals that papers co-authored by
Dr. Eric Poehlman they had published were fraudulent, only eight
had retracted; and even after the Annals of Internal Medicine had
retracted one of these papers, other authors continued to cite it.63
In fact, there are so many recent reports of failures of the
peer-review system that the difficulty is to select the most in-
structive. Should it be the notorious case of Dr. Hwang Woo Suk,
the researcher whose apparently stunning work on cloning, pub-
lished in Science and Nature, turned out to rest on fabricated
data?6 4 Or should it be that extraordinary article in the Journal of
Reproductive Medicine, claiming to have shown that intercessory
60. John P.A. Ionnadis, Contradicted and Initially Stronger Effects in Highly Cited
Clinical Research, 294 JAMA 218, 220 (2005).
61. Lauren Gravitz, Biology's Image Problem, Rockefeller U. Scientist 1, 10 (Spring
2006).
62. Paul J. Friedman, Correcting the Literature following Fraudulent Publication, 263
JAMA 1416, 1417 (1990); Mark P. Pfeiffer & Gwendolyn L. Snodgrass, The Continued Use
of Retracted, Invalid Scientific Literature, 263 JAMA 1420, Abstract (1990).
63. Jennifer Couzin & Katherine Unger, Cleaning up the Paper Trail, 312 Sci. 38, 39
(2006); Harold C. Sox & Drummond Rennie, Research Misconduct, Retraction, and Clean-
sing Medical Literature: Lessons from the Poehlman Case, 144 Annals Internal Med. 609,
609 (2006) (noting that in 1989, in order to evaluate allegations of scientific fraud, Con-
gress created the Office of Scientific Integrity, later renamed the Office of Research Integ-
rity). The article that was retracted was Eric T. Poehlman et al., Changes in Energy Bal-
ance and Body Composition at Menopause: A Controlled Longitudinal Study, 123 Annals
Internal Med. 673 (1995). Sox & Rennie, supra n. 63, at 609.
64. Nicholas Wade & Choe Sang-Hun, Human Cloning Was All Faked, Koreans Re-
port, N.Y. Times Al (Jan. 10, 2006) (quoting Dr. Benjamin Lewin, former editor of Cell,
commenting that Science should have been more careful and certainly shouldn't have
published a paper with "several identical photos").
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prayer by strangers of another faith in another country doubled
the success rate of attempted in vitro fertilizations-the supposed
lead author of which learned of the study only six to twelve
months after it was completed, and another, a law school gradu-
ate with no medical degree or scientific training, subsequently
pled guilty to (unrelated) charges of business fraud?65 Or maybe
the papers by Jon Sudbo in The Lancet and the New England
Journal of Medicine (NEJM), claiming to have shown that non-
steroidal anti-inflammatory drugs reduced the risk of oral cancer,
all of which turned out to have been based on fabricated data?66
Or should it be something lower-key, such as the article in the
NEJM, cited in litigation against Metabolife, in which the infor-
mation in a table of eleven patients listing adverse effects and
pre-existing conditions is contradicted by the text on the very
same page?67
But no: the extraordinary saga of the report of Merck's large-
scale clinical trial of Vioxx, the VIGOR study-on the basis of
which, in May 1999, the FDA approved the drug for sale-stands
65. Benedict Carey, Researcher Pulls His Name from Paper on Prayer and Fertility,
N.Y. Times A15 (Dec. 4, 2004); Bruce Flamm, The Columbia University Miracle' Study:
Flawed and Fraud, 28 Skeptical Inquirer 25, 27-28 (Sept./Oct. 2004). Thanks to Elizabeth
Balbin for this example. The article concerned was Kwang W. Cha et al., Does Prayer In-
fluence the Success of In Vitro Fertilization-Embryo Transfer? Report of a Masked, Ran-
domized Trial, 46 J. Reprod. Med. 781, 782 (2001). Flamm, supra n. 65, at 27-28.
66. The database of 908 participants in the The Lancet study, reportedly, was simply
made up; 250 of the fictional persons involved supposedly had the same birth date! Forbes,
Many Researches Break the Rules: Study, http://www.forbes.comlforbeslife/health/feeds/
hscout/2006/04/13/hscout5321 10.html (Apr. 13, 2006). See also Richard Horton, Expression
of Concern: Non-Steroidal Anti-Inflammatory Drugs and the Risk of Oral Cancer, 367
Lancet 196, 196 (2006) (expressing concern over verbal admission by Sudbo that he fabri-
cated data for the study previously published in The Lancet and acknowledging possible
misconduct in two of his research papers published in the NEJM); Richard Horton, Retrac-
tion-Non-Steroidal Anti-Inflammatory Drugs and the Risk of Oral Cancer: A Nested Case-
Control Study, 367 Lancet 382, 382 (2006) (retracting a Sudbo article from a previous issue
of The Lancet based on confirmation that data was fabricated). The article retracted from
The Lancet was John Sudbo et al., Non-Steroidal Anti-Inflammatory Drugs and the Risk of
Oral Cancer: A Nested Case-Control Study, 366 Lancet 1359 (2005). Id.
67. Christine Haller & Neal L. Benowitz, Adverse Cardiovascular and Central Nervous
System Events Associated with Dietary Supplements Containing Ephedra Alkaloids, 343
New Eng. J. Med. 1833, 1836 (2000). Table four on page 1836 lists patient number seven
as having no pre-existing conditions or concurrent risks, yet the text on the same page
indicates that an autopsy of this patient "showed mild cardiomegaly with four-chamber
dilatation and coronary artery disease, with narrowing of 50 to 75 percent in four vessels."
Thanks to Dr. Robert Myerburg for this example.
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out as an object-lesson in what can go wrong.68 After FDA ap-
proval, the report of the study-concluding that Vioxx carried a
lower risk of adverse gastrointestinal effects than older pain-
relievers, and that for most patients its risk of adverse cardiovas-
cular effects was not significant-was submitted to the NEJM,
where it appeared in November 2000.69 In 2002, however, Merck
was obliged to add a warning about cardiovascular risks to the
package insert. And in September 2004-after the data safety
monitoring board halted another major clinical trial, the AP-
PROVe study (designed to show that Vioxx lowered the risk of
colon polyps), when it emerged that patients given twenty-five
milligrams of Vioxx for more than eighteen months had a fourfold
greater incidence of serious thromboembolic events-Merck with-
drew the drug from the market.70
In December 2005, in the midst of a gathering storm of litiga-
tion by patients claiming they had been injured by the drug, the
NEJM issued an "Expression of Concern" acknowledging that
three heart attacks among patients taking Vioxx had been omit-
ted from the report of the VIGOR study it had published in
2000.71 These adverse events had been included in the data on the
FDA website since February 2001; and two of the three authors
had known of them well in advance of the publication of the pa-
per.72 Their inclusion raised the rate of heart attacks among those
taking Vioxx from the 0.4% claimed in the paper to 0.5% (com-
pared to 0.1% among patients taking naproxen) and moreover
contradicted the claim in the paper that only those already at risk
showed an increase in heart attacks after taking Vioxx. 73 Merck
claimed that the additional heart attacks occurred after the cut-
off date for the study; but the editor of the journal, Dr. Jeffrey
68. Sen. Comm. on Fin., FDA, Merck, and Vioxx: Putting Patient Safety First? 108th
Cong. (Nov. 18, 2004) (testimony of Dr. Sandra Kweder, Dep. Dir., Off. of New Drugs, Ctr.
for Drug Evaluation and Research, FDA).
69. Claire Bombadier et al., Comparison of Upper Gastrointestinal Toxicity of Rofe-
coxib and Naproxen in Patients with Rheumatoid Arthritis, 343 New Eng. J. Med. 1520
(2000).
70. Simon R.J. Maxwell & David J. Webb, Cox-2 Selective Inhibitors-Important Les-
sons Learned, 365 Lancet 449, 449 (2005).
71. David Armstrong, Bitter Pill: How the New England Journal of Medicine Missed
Warning Signs in Vioxx-Medical Weekly Waited Years to Report Flaws in Article that
Praised Pain Drug-Merck Seen as 'Punching Bag', Wall St. J. Al, A10 (May 15, 2006).
72. Id.
73. Id.
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Drazen, told reporters that the design of the study, which contin-
ued to track gastrointestinal effects after it stopped tracking car-
diovascular effects, had been misleading. 74
But the problem here wasn't only with the authors; nor was it
only that the journal's reviewers didn't have the raw data or that
they failed to notice the oddity in the study design. We now know
that in June 2001 the editors of the NEJM had received a letter
from pharmacist Jennifer Hrachovec asking that the article be
corrected in light of the information on the FDA website, but had
declined to publish it on the grounds that the journal "can't be in
the business of policing every bit of data we put out";75 that when
deposed by the parties in federal litigation in Texas in November
2005, executive editor Dr. Gregory Curfman acknowledged that
neither the reviewers nor the editors had questioned Merck's the-
ory that the higher rate of cardiovascular events among Vioxx
patients was attributable to a cardio-protective effect of naproxen,
even though an FDA official had noted that it "is not supported by
any.., controlled trials";76 that the journal had sold 929,000 cop-
ies of reprints of the article, most of them to Merck, for revenue
estimated to be between $697,000 and $836,000; and that the
"Expression of Concern" about the study had been published on
the urgent last-minute advice of public-relations specialist Ed-
ward Cafasso that testimony to be presented the next day in the
Vioxx case in which Dr. Curfman had been deposed made it es-
sential for the journal to post something right away, to "drive the
media away from NEJM and toward the authors, Merck and
plaintiff attorneys."77 As Richard Smith, former editor of the Brit-
ish Medical Journal, observed, the conduct of the NEJM in the
dispute over the VIGOR trial "raised doubts about the journal's
74. Id.
75. Id. (quoting Dr. Jeffrey Drazen, a top editor for the New England Journal of Medi-
cine, during a radio appearance in August 2001).
76. Id.
77. Id. The "Expression of Concern" was published on-line on December 8, 2005, the
day the jury began deliberations in the third Vioxx trial. Diedtra Henderson, Journal Says
Vioxx Woes Suppressed; Merck Blamed; Correction Sought, Boston Globe Al (Dec. 9, 2005).
According to Henderson, in December 2005, Dr. Curfman said that the NEJM had
"learned of the new information [i.e., the three omitted heart attacks] about two weeks
[earlier]"; according to Armstrong, supra n. 71, at Al, however, the journal had known
about them at least since Ms. Hrachovec's letter in June 2001.
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integrity"; "[t]he journal failed its readers [and] damaged its repu-
tation."78
And just as you thought it could hardly get worse, in July
2006 the NEJM published a correction to the report it had earlier
published of the APPROVe study: key results claimed in the re-
port had not been arrived at by the statistical method the authors
said they used; moreover, using the method the authors had said
they were using, but had not in fact used, the results undermined
the claim in the report that cardiovascular risks increased only
after eighteen months. 79
Not long before, Lawrence Altman had written in the New
York Times that "[riecent disclosures of fraudulent or flawed stud-
ies in medical and scientific journals have called [the peer-review
system] into question as never before... ";1o it is hard to disagree.
For obvious reasons they are harder to track, and for obvious
reasons they are often not known until long after the event; but it
is pretty clear that there are also many instances in which impor-
tant and innovative work has been rejected by peer-reviewers.
Lock tells the story of Edward Jenner's report of his smallpox
vaccination, which was rejected by the Transactions of the Royal
Society in 1796, after Sir Joseph Banks had looked it over and
reported that he "wanted faith" in its conclusion.81 Charles
McCutchen, lamenting the way "[r]eviewing weeds out good
manuscripts as well as poor ones," lists "Frederick Lanchester's
1894 circulation theory of how wings lift, Chandra Bose's photon
statistics in 1924, Enrico Fermi's theory of beta decay in 1933,
Herman Almquist's discovery of vitamin K2 in 1935, Hans Krebs'
78. Med. News Today, New England Journal of Medicine Damaged by Its Conduct
over Vioxx, Says Former Editor of British Medical Journal, www.medicalnewstoday.com/
medicalnews.php?newsid=46831 (July 9, 2006).
79. Heather Won Tesoriero, Vioxx Study Correction May Add Pressure to Merck's De-
fense, Wall St. J. A2 (June 27, 2007). The original article was Robert S. Bresalier et al.,
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemopreven-
tion Trial, 352 New Eng. J. Med. 1092 (2005). Correction, 355 New Eng. J. Med. 221, 221
(2006). Ironically enough, at page 1131, the same issue of the journal includes a short
paper by Jeffrey M. Drazen entitled COX-2 Inhibitors-A Lesson in Unexpected Problems.
80. Lawrence K. Altman, For Science's Gatekeepers, a Credibility Gap, N.Y. Times F1
(May 2, 2006).
81. Lock, supra n. 15, at 2.
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citric-acid cycle in 1937, and Raymond Lindeman's trophic-
dynamic concept in ecology in 1941"; all were "turned down at
least once."8 2 David Horrobin adds that Krebs' paper, "possibly
the most important single article in modern biochemistry,...
eventually led to a Nobel prize";8 3 and lists many other examples,
including: a "seminal paper[] in immunology" by Glick et al. on
the identification of B lymphocytes, which "was rejected by lead-
ing general and specialist journals and eventually appeared in
Poultry Science because of the species on which the work was
done";84 and a paper by New Zealand farmer Gladys Reid suggest-
ing that facial eczema in sheep might be caused by a marginal
zinc deficiency, which was rejected by the journals in the field
until Horrobin published it in Medical Hypotheses-after which
her work was confirmed, the disease was eliminated, and Ms.
Reid was awarded a decoration for services to New Zealand agri-
culture.8 5
By now it should hardly need saying: the fact that work has
passed pre-publication peer review is no guarantee that it is not
flawed or even fraudulent; and the fact that work has been rejected
by reviewers is no guarantee that it is not an important advance.
-V. LESSONS FOR LAWYERS
"Enough already!" you may be thinking. To be sure, Judge
Kozinski's confidence that "the normal peer[-]review process... is
one of the hallmarks of reliable scientific investigation" was over-
optimistic;8 6 but didn't Justice Blackmun clear all this up, more
than a decade ago, in his majority opinion in Daubert?7
Well, evidently Justice Blackmun paid attention to the brief
from amici Chubin et al.,8 8 for he acknowledged the following:
82. Charles W. McCutchen, Peer Review: Treacherous Servant, Disastrous Master, 94
Tech. Rev. 28, 33 (Oct. 1991).
83. David F. Horrobin, The Philosophical Basis of Peer Review and the Suppression of
Innovation, 263 JAMA 1438, 1440 (1990). This paper was cited by the majority in Daubert
(1993), 509 U.S. at 593.
84. Horrobin, supra n. 83, at 1440.
85. Id.
86. Daubert (1991), 951 F.2d at 1131 n. 3.
87. See Daubert (1993), 509 U.S. at 593 (establishing that whether an idea has been
subject to peer review is a "pertinent consideration").
88. Pressured to save money and publish on schedule, editors of peer-reviewed jour-
nals can sometimes publish the "scientific equivalent of a supermarket tabloid." Amici Br.
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Publication (which is but one element of peer review) is not a
sine qua non of admissibility; it does not necessarily corre-
late with reliability.., and in some instances well-grounded
but innovative theories will not have been published ....
But submission to the scrutiny of the scientific commu-
nity... increases the likelihood that substantive flaws in
methodology will be detected.8 9
It would have been desirable to have made the distinction be-
tween the broad and the narrow senses of "peer review" more ex-
plicit; nevertheless, what Justice Blackmun had in mind seems
reasonably clear; moreover, it seems true: poor scientific work
may pass pre-publication peer review, and good work may not,
but when scientific work is published and made available for the
scrutiny of other scientists, the likelihood increases that, eventu-
ally, any serious methodological flaws will be spotted. And Justice
Blackmun's advice about the weight courts should give this
"Daubert factor"-in effect, that it's a relevant consideration, but
not necessarily a decisive one-seems at first blush quite unex-
ceptionable:
The fact of publication (or lack thereof) in a peer[-]reviewed
journal thus will be a relevant, though not dispositive, con-
sideration in assessing the scientific validity of a particular
technique or methodology on which an opinion is premised.90
"At first blush"; but at second blush you find yourself beset by
worries, both theoretical and practical: the meaning of "reliable"
threatens to unravel into indeterminacy; and the Court's advice
about the bearing of peer review on the determination of reliabil-
ity sounds less and less helpful. Ambiguities strike one almost
immediately: are courts to ask whether the work on which prof-
fered testimony is based was published after surviving peer re-
view, or is it enough that it be published in a "peer[-]review jour-
nal"? Should the witness's work have been subject to peer review
of Chubin, supra n. 7, at 12. A compromise between "absolute certainty" in the validity of
the scientific claims in the articles and "absolute speed and absolute economy" means that
"mistakes become inevitable and that erroneous, misleading, and fraudulent reports are
sometimes published." Id.
89. Daubert (1993), 509 U.S. at 593.
90. Id. at 594.
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and publication, or is it enough that the witness rely on others'
peer-reviewed and published work? And so on.
Justice Blackmun's sense that survival of the long-run scru-
tiny of the scientific community is about the best indicator of sci-
entific validity a layperson can have, albeit a fallible one, is per-
fectly correct; but it is of no real practical help. For obvious rea-
sons the scientific issues at stake in legal cases are not likely to
turn on the most firmly established science, but on the still-
controversial stuff; and it would be hopelessly unrealistic to imag-
ine that courts could somehow figure out which still-controversial
scientific claims will, eventually, survive such "peer review,"
when scientists themselves cannot.
And rather than clarifying the concept of "evidentiary reli-
ability" (which the Daubert Court equates with "scientific valid-
ity"), 91 Justice Blackmun's observations contribute to its obscu-
rity.92 In ordinary speech, "reliable" has a whole tangle of uses:
but whether we are describing inanimate objects, like clocks or
cars, or persons (also called "informants," or "sources"), or infor-
mation, data-bases, etc., reliability-fitness to be relied upon-is
ordinarily conceived as a matter of degree. But the Daubert ruling
is about admissibility, which is not a matter of degree; and so
obliges us to adopt a categorical conception.
If evidence must be reliable enough to be admissible, how re-
liable does it have to be, and how is a court to determine whether
evidence meets the standard? (Is the same degree of reliability to
be imposed on "soft" scientific evidence as on "hard," or on non-
scientific expert testimony as on the scientific?) It seems to make
sense, as Judge Becker argued in In re Paoli Railroad Yard PCB
Litigation, that "[t]he evidentiary requirement of reliability
[should be] lower than the merits standard of correctness";93 for if
the threshold for admissibility were as high as the standard of
proof, a party seeking to introduce expert testimony would be re-
91. Id. at 591.
92. "Many factors will bear on the inquiry, and we do not presume to set out a defini-
tive checklist or test. But some general observations are appropriate." Id. at 593. Under
Daubert (1993), the key factors in determining evidentiary reliability, or scientific validity,
are whether a theory or technique can be and has been tested, whether it has been subject
to peer review, the known or potential rate of error, the standards controlling the tech-
nique's operation, and "general acceptance." Id. at 593-594.
93. In re Paoli R.R. Yard PCB Litig., 35 F.3d 717, 744 (3d Cir. 1994).
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quired, in effect, to prove his case twice-and the court would be
trespassing on the jury's turf. But now you start to wonder: is
peer-reviewed publication enough, after all, to guarantee that
proffered evidence meets a minimal threshold standard of reli-
ability? If not, is it at least enough to guarantee that, even if the
conclusions drawn are unreliable, the methodology followed meets
minimal standards? Isn't that what Judge Kozinski had in mind
when he wrote in 1995 that peer-reviewed publication "is a sig-
nificant indication. . . that it meets at least the minimal criteria
of good science"?94
Justice Blackmun's ruling for the Court leaves all this open.95
Chief Justice Rehnquist's ruling for the Court in General Electric
Co. v. Joiner, casting doubt on the robustness of the distinction
between methodology and conclusions on which Daubert had re-
lied, is no help. 96 And Justice Breyer's opinion for Kumho Tire Co.
v. Carmichael-holding that Daubert gatekeeping extends to non-
scientific as well as scientific testimony, but that courts may use
any, all, or none of the Daubert factors, and/or other factors more
appropriate to the task at hand-confirms that the tricky stuff is
to be left to courts' discretion. 97
It is no surprise that the Daubert Court did not come up with
a precise formula for deciding questions of evidentiary reliability;
even if such a thing were feasible, it would probably be, not desir-
able precision, but the kind of "[d]elusive exactness" Oliver
Wendell Holmes once decried as "a source of fallacy throughout
the law."98 And, especially given that "peer review and publica-
tion" is only one factor on Daubert's flexible list, perhaps it is no
surprise, either, to find no clear correlation of decisions to admit,
94. Daubert (1995), 43 F.3d at 1318 (emphasis added).
95. Supra nn. 91-94 and accompanying text.
96. Gen. Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997) (asserting that "conclusions and
methodology are not entirely distinct from one another").
97. Kumho Tire Co. v. Carmichael, 526 U.S. 137, 141 (1999). The Court held that
Daubert's general holding-setting forth the trial judge's "gatekeeping" obligation-
applies not only to testimony based on "scientific" knowledge, but also to testimony
based on "technical" and "other specialized" knowledge.... [A] trial court may con-
sider one or more of the more specific factors that Daubert mentioned when doing so
will help .... But ... Daubert's list of specific factors neither necessarily nor exclu-
sively applies to all experts or in every case.
Id.
98. Truax v. Corrigan, 257 U.S. 312, 342 (1921) (Holmes, J., dissenting).
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or to exclude, proffered expert testimony, and whether or not it
satisfies this factor. Instead:
(1) some courts (citing Justice Blackmun's concession that
peer-reviewed publication is not a sine qua non of ad-
missibility) have admitted expert testimony not based
on work that has been peer-reviewed and published;99
(2) some courts (citing Justice Blackmun's concession that
peer-reviewed publication does not necessarily corre-
late with reliability) have excluded expert testimony
based on work which has been peer-reviewed and pub-
lished; 00
(3) some courts (citing Justice Blackmun's acknowledg-
ment that peer-reviewed publication is a pertinent
consideration) have admitted testimony in part be-
99. See e.g. Ruiz-Troche v. Pepsi Cola of Puerto Rico Bottling Co., 161 F.3d 77, 84 (lst
Cir. 1998) (reversing the district court's exclusion of Dr. O'Donnell's testimony regarding
the effects of cocaine on a driver's behavior, on the grounds that, although the secondary
sources he cited were not peer-reviewed or published, other peer-reviewed, published stud-
ies made the same point); Kannankeril v. Terminix Intl., Inc., 128 F.3d 802, 809 (3d Cir.
1997) (vacating and remanding the lower court's decision, which had excluded Dr. Gerson's
testimony, arguing that "although Dr. Gerson did not write on the topic, his opinion is
supported by widely accepted scientific knowledge of the harmful nature of organophos-
phates," and noting that McCullock v. H. B. Fuller Co., 61 F.3d 1038, 1042 (2d Cir. 1995)
held that peer review, publication, and general acceptance go to the weight, not the admis-
sibility, of evidence); Metabolife Intl., Inc. v. Wornick, 264 F.3d 832, 843 (9th Cir. 2001)
(citing Daubert (1995), 43 F.3d at 1317, for the proposition that "when research is begun
pre-litigation, it may be reliable without peer review"); U.S. v. Hankey, 203 F.3d 1160,
1168 (9th Cir. 2000) (holding that the district court did not abuse its discretion in admit-
ting the testimony of a police expert on gang codes and citing Kumho, 526 U.S. at 1176,
saying a court must have latitude not only in deciding whether to admit expert testimony,
but also in deciding "how to test an expert's reliability").
100. See e.g. Allison v. McGhan Med. Corp., 184 F.3d 1300, 1313, 1316, 1319 n. 24 (11th
Cir. 1999) (upholding lower court's exclusion of experts' testimony on role of silicone breast
implants in causing the plaintiffs injuries, in part on the grounds that the fact that a
study was peer-reviewed and published "does not mean it constituted an adequate basis"
for experts' opinion, that "scrutiny by one's peers does not insure admissibility," and that
the fact that a witness had published many articles in peer-reviewed journals "does not
substantiate the scientific validity of his premise"); U.S. v. Cordoba, 194 F.3d 1053, 1059
(9th Cir. 1999) (upholding the district court's exclusion of polygraph evidence, even though
hundreds of articles have been published on polygraphs, including many in peer-reviewed
journals).
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cause it was based on peer-reviewed and published
work;10 1 and
(4) some courts (also citing Justice Blackmun's acknowl-
edgment that peer-reviewed publication is a relevant
factor) have excluded testimony in part because it was
not so based. 10 2
Nor, given Justice Blackmun's shifts from broader to narrower
senses of "peer review," is it altogether surprising that some
courts have interpreted "peer review" to cover kinds of exposure
to other people in a field other than pre-publication peer re-
view. 10 3 Nor is it any surprise that "peer review and publication"
has found its way into courts in states that have not adopted
101. See e.g. In re Silicone Gel Breasts Implants Products Liab. Litig., 318 F. Supp. 2d
879, 896 (C.D. Cal 2004) (finding that Dr. Neugebauer's analysis and criticism of the exist-
ing epidemiological evidence is admissible, in part because "[t]he statistical underpinnings
of epidemiology.., have been subjected to peer review and publication").
102. See e.g. Berry v. City of Detroit, 25 F.3d 1342, 1350-1351 (6th Cir. 1994) (excluding
testimony regarding police training of the plaintiffs' witness Leonard Postill, in part on the
grounds that "[t]here certainly is no testimony as to any peer review of Postill's theory");
Natl. Bank of Com. v. Associated Milk Producers, 191 F.3d 858, 864-865 (8th Cir. 1999)
(affirming the lower court's exclusion of expert's testimony as to connection between afla-
toxin M-1 (AFM) and the plaintiffs cancer in part on the grounds that "[tihere are no sci-
entific studies or medical literature that show any correlation between AFM and laryngeal
cancer"); Nelson v. Tenn. Gas Pipeline Co., 1998 WL 1297690 at **8-9, 13 (W.D. Tenn.
Aug. 31, 1998) (excluding the testimony of Nelson's experts Drs. Kilburn and Hirsch that
the plaintiffs' injuries were caused by PCB exposure from the gas pipeline, in part on the
grounds that their work had not been published or peer-reviewed).
103. See e.g. U.S. v. Bonds, 12 F.3d 540, 559-560 n. 16, 568 (6th Cir. 1993) (affirming
the lower court's decision to admit FBI's expert testimony on DNA, even though "many of
the articles introduced as ... exhibits did not appear in a 'peer-reviewed journal' in the
strict sense of that term," since "all of the articles gave the FBI's procedures exposure
within the scientific community"); U.S. v. Havvard, 117 F. Supp. 2d 848, 854 (S.D. Ind.
2000) (admitting the FBI's fingerprint-identification testimony, arguing and concluding
that it satisfies Daubert; in particular, a fingerprint examiner's methods are subject to
peer review because "any other qualified examiner can compare the objective information
upon which the opinion is based and may render a different opinion if warranted"), aff'd,
260 F.3d 597 (7th Cir. 2001). Havvard, I believe, stretches the meaning of "peer review"
well beyond all reasonable limits.
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Daubert,10 4 and even into cases involving quite different issues
from questions of admissibility of expert testimony.105
But it is disappointing to find that courts' analyses of "peer
review and publication" seem to have been, mostly, quite shallow.
For our investigation of the virtues and vices of the pre-
publication peer-review system has suggested a whole raft of
questions that might throw light on the significance of the fact
that the expert testimony proffered in a given case is, or is not,
based on work published in a peer-reviewed journal. How episte-
mologically respectable is the field in question,'0 6 and are there
serious ongoing methodological disagreements? Is this a highly
regarded journal in the field, or a second- or third-tier publica-
tion-or a last resort of the desperate-to-publish? Was work pub-
lished in a "peer-review journal" in fact peer-reviewed, or was it
published by editorial privilege, or invited? If it was peer-
reviewed, were the reviewers suggested by the author(s)? If it was
invited, was this because of the author's good reputation, or be-
cause of his or her personal relationship with the editor? Is the
author (or an author) associated with the journal, e.g. by serving
on the editorial board? Does the journal in which the work was
published receive support, direct or indirect, from one of the par-
ties to the case or to closely related litigation? Was the work re-
jected by other journals before being accepted by this one, and if
so, by how many, and which, and on what grounds? If testimony
is based on work which has not been published, is that because it
is too recent, or because, though not recent, it was never submit-
ted for publication, or because it was submitted, but was rejected?
104. See e.g. Berry v. CSX Transp., Inc., 709 So. 2d 552, 569-570 (Fla. 1st Dist. App.
1998) (arguing that even under Frye "[wlhile the existence of numerous peer-reviewed,
published.., studies does not guarantee that the studies are without flaws, such publica-
tion ... alleviates the necessity of thorough judicial scrutiny ... at the admissibility
stage").
105. See e.g. Kitzmiller v. Dover Area Sch. Dist., 400 F. Supp. 2d 707, 743-745 (M.D. Pa.
2005) (finding that, while the plaintiffs' experts' testimony is based on peer-reviewed lit-
erature, defendants' experts' testimony is not based on material that has been subject to
peer review, which is "exquisitely important" in the scientific process, helping to ensure
"that research papers are scientifically accurate[ ], meet the standards of the scientific
method, and are relevant to other scientists in the field").
106. See Kumho, 526 U.S. at 151 ("[n]or... does the presence of Daubert's general
acceptance factor help show that an expert's testimony is reliable where the discipline
itself lacks reliability").
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Have there been subsequent expressions of concern or retrac-
tions, 107 or have other papers criticized the work?
These are not easy questions to answer, and it is not remark-
able that courts have not routinely asked them. But when some of
them were explored by a court-as it happens, in another Bendec-
tin case, less well-known than Daubert-the results were instruc-
tive, to say the least; and quite disturbing.
V. FULL CIRCLE? "PEER REVIEW AND PUBLICATION"
IN THE BENDECTIN LITERATURE
Blum v. Merrell Dow Pharmaceuticals10 8 was a long, drawn-
out Bendectin case from the Pennsylvania courts which began
several years before Daubert, in 1982, but was not finally con-
cluded until 2000.109 (No, Pennsylvania has not adopted Daubert,
but remains a Frye state; don't forget, however, that Daubert
(1989) was a rare instance in which Frye had been used in a civil
case, and that the Supreme Court granted certiorari to settle
whether Frye had been superseded by the Federal Rules of Evi-
dence.)
In Blum as in Daubert, Merrell Dow's attorneys argued that
the plaintiffs' expert testimony should be excluded, on the
grounds that it was not generally accepted in the relevant scien-
tific community. 110 The Blums' attorneys argued, however, that
Merrell Dow's expert testimony should be excluded, on the
grounds that the supposed "scientific consensus" on the matter
was completely artificial; that it had been created, in fact, by the
defendant manufacturer's support of favorable research and-the
key point for our purposes-by Merrell Dow's support of ques-
107. To find retractions in medical journals, visit PubMed (available at http://www.ncbi
.nlm.nih.gov/entrez/query.fcgi?db=PubMed&itool=toolbar) and search for "retracted publi-
cation" in the MeSH (Medical Subject Heading) database, then click on Links and select
PubMed.
108. 764 A.2d 1.
109. Blum, 764 A.2d at 1 (final appeal decided December 22, 2000); Blum, 1 Pa. D. & C.
4th 634, 635 (Pa. Com. Pleas Ct. 1988), aff'd, 626 A.2d 537 (Pa. 1993) (lawsuit filed on
September 13, 1982).
110. Blum v. Merrell Dow Pharms., Inc., 705 A.2d 1314, 1319 (Pa. Super. 1997), aff'd,
764 A.2d 1 (Pa. 2000).
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tionably peer-reviewed journals that would publish results helpful
to the company in defending itself against Bendectin litigation.11'
Judge Bernstein's ruling at the second trial in 1996 includes
a devastating summary of the testimony of Merrell Dow's ex-
perts.11 2 Defense expert Dr. Bracken acknowledges not only that
articles that are "less than good" can pass peer review, but also
that his own published study of Bendectin and birth defects was
itself less than good.113 Defense expert Dr. Klebanoff testifies that
Bendectin does not cause birth defects, but then admits that his
own article showed a statistically significant association with
congenital cataracts, underdeveloped lungs, and microcephaly.11 4
Defense expert Dr. Shapiro (whose unit at Boston University had
received over one-and-a-half million dollars from Merrell Dow)
testifies that a drug taken by a mother after the time of fetal limb
formation could not cause a limb defect; but acknowledges under
cross-examination that the data on which his opinion was based
lumped together women who took Bendectin in the period in
which fetal limbs were forming, and women who took it later, and
that for this reason his study had been criticized in subsequent
articles.115 Defense expert Dr. Newberne, Merrell Dow's Vice-
President responsible for animal testing and drug safety, testifies
that while a study by Dr. Smithells concluding that Bendectin is
not teratogenic was being reviewed and rejected by the British
Medical Journal, The Lancet, and the NEJM, and finally accepted
by a much less prestigious journal, Teratology, Dr. Smithells was
actively soliciting funds from the company: "Much clearly depends
upon the value of this publication to Merrell Dow," Dr. Smithells
wrote, since it "may save the company large sums of money.., in
the California court .... 16
111. See Blum, 764 A.2d at 8 (Castille, J., dissenting).
112. Blum v. Merrell Dow Pharms., Inc., 33 Phila. Co. Rptr. 193, 206-207 (Pa. Com.
Pleas Ct. 1996).
113. Id. at 208. Dr. Bracken's study was based on interviews with 1,427 mothers, 122 of
whom had taken Bendectin during pregnancy, and showed a statistically significant in-
creased risk of birth defects when a mother used Bendectin and smoked. Id. at 207.
114. Id. at 208-209. On cross-examination Dr. Klebanoff testified that the positive
association between Bendectin and clubbed feet, though not statistically significant, met
the standard he used in his article for cataracts and vomiting; he agreed that an article
that is "less than good" may pass peer review. Id.
115. Id. at 214-216.
116. Id. at 217, 219. Dr. Newberne also acknowledged that after a first study by Dr.
Hendrickx found a statistically significant increase in heart defects in Bendectin-treated
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And the editor of Teratology, Dr. Robert Brent, 117 who has
been retained as an expert by Merrell Dow for eighteen years,
testifies that his only formal education in epidemiology was one
course in statistics, but that he considers himself a world author-
ity on "secular trend data"-a field in which, Judge Bernstein
comments, he is apparently the only practitioner.1 1 8 Using his
editorial prerogative to sidestep peer review,11 9 he had published
in his own journal an article entitled Litigation-Produced Pain,
Disease, and Suffering: An Experience with Congenital Malforma-
tion Lawsuits, based on his review of depositions and trial tran-
scripts, and concluding that seventeen out of seventeen plaintiffs
lied;120 and he had submitted a draft article entitled Bendectin:
The Most Comprehensively Studied Human Non-Teratogen, and
the Foremost Tortogen-litigen to Merrell Dow's attorney for edit-
ing, hoping to publish it in NEJM, JAMA, or The Lancet.121
Eventually, Merrell Dow prevailed. In 2000, the Pennsyl-
vania Supreme Court ruled that while the Blums' expert testi-
mony was arguably admissible under Daubert, "a standard some-
what less exacting than that of Frye," it was inadmissible under
the Frye rule.1 22 In dissent, however, Justice Castille reminded
his colleagues that the trial court, citing Frye, had been impressed
monkeys, Merrell Dow funded a second study that arrived at results more favorable to the
company. Id. at 221. The entry in Merrell Dow's financial records was: "Hendrickx' mon-
key study--defense." Id.
117. Dr. Brent's testimony was found to be incredible because "[his] testimony and
manner suggested a degree of conviction in his own conclusions unwarranted in a disci-
pline in which ... explanations are only more or less probable." Blum, 764 A.2d at 10-11
(Castille, J., dissenting) (quoting Wells v. Ortho Pharm. Corp., 615 F. Supp. 262, 291 (N.D.
Ga. 1985)).
118. Blum, 33 Phila. Co. Rptr. at 223-224.
119. See id. at 224 (explaining that some of Dr. Brent's writings had been published in
Teratology solely "because of his personal editorial prerogative").
120. Blum, 33 Phila. Co. Rptr. at 225; Robert L. Brent, Litigation-Produced Pain, Dis-
ease, and Suffering: An Experience with Congenital Malformation Lawsuits, 16 Teratology
1, 5 tbl. 1 (Aug. 1997).
121. Blum, 33 Phila. Co. Rptr. at 225. The article in question had in fact been pub-
lished, though Judge Bernstein's ruling does not tell us this. See Robert L. Brent, Bendec-
tin: Review of the Medical Literature of a Comprehensively Studied Human Nonteratogen
and the Most Prevalent Tortogen-Litigen, 9 Reproductive Toxicology 337 (1995) (published
version of Dr. Brent's article). The article prompted a lawsuit for defamation against Dr.
Brent by Dr. Stuart Newman, who was one of the plaintiffs' experts in Blum and whom Dr.
Brent misquoted. Newman v. Brent, 1998 U.S. Dist. LEXIS 10476 (D.D.C. 1998).
122. Blum, 764 A.2d at 3-4. Despite the Blum Court's rhetoric, however, it is question-
able, to say the least, whether Daubert really is "less exacting" than Frye.
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by the fact that "the scientific consensus [on Bendectin] derives
largely from the proprietary influence and litigation interests of
the adverse party," and that "much of the 'science' in this area,
held up by Merrell Dow as the objective, generally accepted scien-
tific view that requires exclusion of the plaintiffs' experts' 'con-
trary' conclusions, itself was a product of Merrell Dow's litigation-
driven influence."' 23
But for our purposes, it is Judge Bernstein's conclusions that
are most apropos: The testimony in this case, he observes, "dem-
onstrates how 'scientific consensus' can be created through pur-
chased research and the manipulation of a 'scientific' literature,
funded as part of litigation defense, and choreographed by coun-
sel."124 It "clearly demonstrated that not all 'peer review' journals
are created equal," that "not all the articles contained in 'peer re-
view' journals were even reviewed. . . ," and that "[a]rticles were
intentionally inserted in peer review journals for use in court."'125
And in Appendix B to his opinion, entitled "Science and Justice,"
Judge Bernstein adds the following:
The testimony demonstrated medical- scientific peer[-]review
journal literature created and manipulated for use in the
courts .... The testimony demonstrated that articles were
inserted in "peer review" journals, without review by inde-
pendent authorities, but edited by lawyers... [and] revealed
factual editing of supposedly scientific research literature by
the very lawyers defending in litigation.126
The example is instructive, reinforcing Justice Blackmun's
acknowledgement that peer-reviewed publication is no guarantee
of "scientific validity" but at best a very fallible indicator; and re-
minding us that if courts were to pursue the questions suggested
here, this Daubert factor could, and should, be handled with more
caution, and more subtlety, than it has usually been up to now. It
is also quite disturbing; for it suggests that the scientific litera-
123. Id. at 9, 11 (Castille, J., dissenting) (emphasis in original).
124. Blum, 33 Phila. Co. Rptr. at 230.
125. Id. at 246-247.
126. Id. at 248-249.
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ture in the litigation by way of which "peer review and publica-
tion" entered the official legal vocabulary of admissibility may
have been tainted by litigation interests. Ironically, it seems that
the same commercialization of medical research that has contrib-
uted to the creeping corruption of peer review and publication
may also have been partly responsible for the legal system's com-
ing to rely on that process as a factor in determining evidentiary
reliability. 127
127. My thanks to Mark Migotti for helpful comments on two drafts; to Lee Tilson and
Susan Shott for help in finding material on statistical errors in, and retractions of, pub-
lished articles; and to the several librarians at the University of Miami Law Library, espe-
cially David Hollander and Barbara Brandon, who helped me find relevant material.
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